• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

每日使用皮质类固醇的杜氏肌营养不良症患者的 6 分钟步行距离测量的活动能力和疾病进展。

Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.

机构信息

Child Neurology, University Hospitals Leuven, Leuven, Belgium.

出版信息

Neuromuscul Disord. 2013 Aug;23(8):618-23. doi: 10.1016/j.nmd.2013.05.006. Epub 2013 Jun 13.

DOI:10.1016/j.nmd.2013.05.006
PMID:23770101
Abstract

In order to understand contemporary natural history of Duchenne muscular dystrophy (DMD), we report 6-minute walk distance (6MWD) and its change over time from a large single centre population of corticosteroid treated DMD boys. Sixty-five boys on daily corticosteroid treatment were identified with a mean (SD) age of 9.5 (2.3) years at first observation. 6MWD was described for 1year age groupings. In addition, changes in 6MWD at 1, 1.5 and 2years (±12weeks) of follow-up were evaluated. The same evaluations were applied to 6MWD data converted to percent predicted values based on the Geiger equation. 6MWD showed an increase from age group 4.5-5.5years to age group 6.5-7.5years, followed by a decline, which became precipitous from 12.5years onwards. From 15.5years, all boys were unable to perform the 6-min test. Changes in 6MWD demonstrated a mean (median, SD) decline of -43 (-14, 90) m at 1year (N=25, mean baseline age 9.5years), -64 (-56, 99) m at 1.5years (N=18, mean baseline age 9.6years), -125 (-106, 139) m at 2years (N=14, mean baseline age 10.0years). Conversion to percent predicted values showed the same pattern of evolution.This study provides data on the ambulatory capacity and its changes over time in a homogenous cohort of 65 DMD boys on daily corticosteroids. The variability, the age-related aspects and the slope of decline of the 6MWD should be considered in the design and interpretation of therapeutic trials in ambulant DMD patients.

摘要

为了了解杜氏肌营养不良症(DMD)的当代自然史,我们报告了大剂量糖皮质激素治疗的 DMD 男孩的 6 分钟步行距离(6MWD)及其随时间的变化。在首次观察时,我们确定了 65 名每天接受糖皮质激素治疗的男孩,平均(SD)年龄为 9.5(2.3)岁。6MWD 按 1 年年龄分组进行描述。此外,还评估了 1 年、1.5 年和 2 年(±12 周)随访时 6MWD 的变化。同样的评估也适用于基于 Geiger 方程转换为预测百分比值的 6MWD 数据。6MWD 从 4.5-5.5 岁年龄组增加到 6.5-7.5 岁年龄组,然后下降,从 12.5 岁开始急剧下降。从 15.5 岁开始,所有男孩都无法进行 6 分钟测试。6MWD 的变化显示,在 1 年时(N=25,平均基线年龄为 9.5 岁),6MWD 下降了-43(-14,90)m,平均(中位数,SD)为-64(-56,99)m 在 1.5 年(N=18,平均基线年龄为 9.6 岁),在 2 年(N=14,平均基线年龄为 10.0 岁)时,6MWD 下降了-125(-106,139)m。转换为预测百分比值显示出相同的演变模式。本研究提供了在每日接受糖皮质激素治疗的 65 名 DMD 男孩同质队列中,关于随时间推移的步行能力及其变化的数据。在设计和解释能够行走的 DMD 患者的治疗试验时,应考虑 6MWD 的可变性、与年龄相关的方面和下降斜率。

相似文献

1
Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.每日使用皮质类固醇的杜氏肌营养不良症患者的 6 分钟步行距离测量的活动能力和疾病进展。
Neuromuscul Disord. 2013 Aug;23(8):618-23. doi: 10.1016/j.nmd.2013.05.006. Epub 2013 Jun 13.
2
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.6 分钟步行试验作为杜氏肌营养不良症的一种新的疗效评价指标。
Muscle Nerve. 2010 Apr;41(4):500-10. doi: 10.1002/mus.21544.
3
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.对杜兴氏肌营养不良症患者通过6分钟步行距离测量的动态功能自然史轨迹进行分类。
Neuromuscul Disord. 2016 Sep;26(9):576-83. doi: 10.1016/j.nmd.2016.05.016. Epub 2016 May 27.
4
Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.参与drisapersen DMD114673研究的杜氏肌营养不良症受试者与每日服用皮质类固醇的匹配自然史队列受试者的活动能力和疾病进展比较。
Neuromuscul Disord. 2017 Mar;27(3):203-213. doi: 10.1016/j.nmd.2016.11.013. Epub 2016 Nov 25.
5
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.依特醇治疗无义突变型杜氏肌营养不良症(ACT DMD)患者的疗效:一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2017 Sep 23;390(10101):1489-1498. doi: 10.1016/S0140-6736(17)31611-2. Epub 2017 Jul 17.
6
Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.口服皮质类固醇与杜氏肌营养不良症心肌病的发病。
J Pediatr. 2013 Oct;163(4):1080-4.e1. doi: 10.1016/j.jpeds.2013.05.060. Epub 2013 Jul 15.
7
Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.杜氏肌营养不良症男孩的6分钟步行测试与加速度计功能结果之间存在强相关性。
J Child Neurol. 2015 Mar;30(3):357-63. doi: 10.1177/0883073814530502. Epub 2014 Apr 23.
8
The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.6 分钟步行试验和杜氏肌营养不良症的其他终点:来自一项多中心研究的 48 周纵向自然史观察。
Muscle Nerve. 2013 Sep;48(3):343-56. doi: 10.1002/mus.23902. Epub 2013 Jun 26.
9
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.杜氏肌营养不良症患者6分钟步行距离变化的个体化预测
PLoS One. 2016 Oct 13;11(10):e0164684. doi: 10.1371/journal.pone.0164684. eCollection 2016.
10
The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.杜氏肌营养不良症/贝克肌营养不良症的 6 分钟步行试验:纵向观察。
Muscle Nerve. 2010 Dec;42(6):966-74. doi: 10.1002/mus.21808.

引用本文的文献

1
Trunk-oriented Exercises Versus Whole-body Vibration on Abdominal Thickness and Balance in Children with Duchene Muscular Dystrophy.躯干定向运动与全身振动对杜氏肌营养不良症患儿腹部厚度和平衡的影响。
J Musculoskelet Neuronal Interact. 2024 Mar 1;24(1):47-54.
2
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.行业指南草案:杜氏肌营养不良症、贝克肌营养不良症和相关肌营养不良症——为整个疾病谱开发潜在的治疗方法。
J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219.
3
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
肌动单位电位持续时间评估作为 DT-DEC01 细胞疗法治疗杜氏肌营养不良症患者 12 个月内系统性-骨内给药疗效的生物标志物。
Arch Immunol Ther Exp (Warsz). 2023 Nov 24;71(1):24. doi: 10.1007/s00005-023-00691-y.
4
Upper Limb Changes in DMD Patients Amenable to Skipping Exons 44, 45, 51 and 53: A 24-Month Study.可跳过外显子44、45、51和53的杜氏肌营养不良症患者上肢变化:一项为期24个月的研究。
Children (Basel). 2023 Apr 19;10(4):746. doi: 10.3390/children10040746.
5
Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy.双能 X 射线吸收法测量的瘦体重可作为杜氏肌营养不良症男孩病情进展的生物标志物。
Sci Rep. 2022 Nov 5;12(1):18762. doi: 10.1038/s41598-022-23072-5.
6
Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy.贝叶斯建模和模拟在罕见病药物开发早期决策中的应用:以杜氏肌营养不良症为例。
PLoS One. 2022 Apr 28;17(4):e0247286. doi: 10.1371/journal.pone.0247286. eCollection 2022.
7
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.一项长期前瞻性和回顾性比较研究的功能结局表明,长期依替膦酸酯治疗可延迟步行能力丧失和肺功能下降。
J Neuromuscul Dis. 2022;9(1):39-52. doi: 10.3233/JND-210665.
8
Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests.定量肌肉 MRI 生物标志物在杜氏肌营养不良症中的应用:与年龄和功能测试的横断面相关性。
Biomark Med. 2021 Jun;15(10):761-773. doi: 10.2217/bmm-2020-0801. Epub 2021 Jun 22.
9
Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.依特司群治疗与匹配自然病史对照的杜氏肌营养不良症患者的长期门诊功能比较。
J Neuromuscul Dis. 2021;8(4):469-479. doi: 10.3233/JND-200548.
10
Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy.基于层次贝叶斯模型的疾病进展研究,为中心核肌病临床试验设计提供信息。
Orphanet J Rare Dis. 2021 Jan 6;16(1):3. doi: 10.1186/s13023-020-01663-7.